Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development

Sirnaomics, a biopharmaceutical company focused on discovering and developing innovative drugs for indications with medical needs and large market opportunities, has announced the advancement of STP705 into late-stage clinical development for the treatment of Squamous Cell Carcinoma in situ (isSCC). The decision follows encouraging Phase IIa and Phase IIb clinical results that were shared with t..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 20.
  • textsms

AstraZeneca and Sanofi's Pediatric RSV Antibody Receives Unanimous Backing from FDA Panel

AstraZeneca and Sanofi have received unanimous backing from the FDA’s Antimicrobial Drugs Advisory Committee for their respiratory syncytial virus (RSV) antibody, nirsevimab, for use in the pediatric setting. Nirsevimab is an investigational long-acting antibody that targets and binds to the part of the RSV virus that attaches to the host’s cells. If approved, nirsevimab would become the first i..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 11.
  • textsms

AstraZeneca and Sanofi's Pediatric RSV Antibody Receives Unanimous Backing from FDA Panel

Pharmaceutical companies AstraZeneca and Sanofi have received unanimous approval from the FDA's Antimicrobial Drugs Advisory Committee for their respiratory syncytial virus (RSV) antibody, nirsevimab, to be used in pediatric settings. The committee voted 21-0 in favor of approving the immunizing antibody for use in infants during their first RSV season, while also recommending its approval for h..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms